Assi, Mohamad
Kimmelman, Alec C. http://orcid.org/0009-0002-9465-8411
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA232124, P01CA117969, P30CA016087-38, 1R01CA251726-01A1)
Lustgarten Foundation (SU2C)
Article History
Received: 14 July 2022
Accepted: 20 March 2023
First Online: 17 April 2023
Competing interests
: A.C.K. has financial interests in Vescor Therapeutics and is an inventor on patents pertaining to KRAS-regulated metabolic pathways and redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, targeting alanine transport and the autophagic control of iron metabolism. A.C.K. is on the scientific advisory board of Rafael/Cornerstone Pharmaceuticals, is an advisor for OncoRev and has been a consultant for Deciphera and AbbVie. The other author declares no competing interests. M.A. is postdoctoral fellow at New York University Langone Health.